$338 Million is the total value of Sands Capital Ventures, LLC's 23 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 66.7% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
SNOW | Buy | SNOWFLAKE INCcl a | $32,967,613 | -13.2% | 215,799 | +0.0% | 9.75% | -13.1% |
New | RAYZEBIO, INC. | $26,542,076 | – | 1,195,589 | +100.0% | 7.85% | – | |
New | KLAVIYO, INC. | $16,195,370 | – | 469,431 | +100.0% | 4.79% | – | |
CRWD | Buy | CROWDSTRIKE HLDGS INCcl a | $144,784 | +32.5% | 865 | +16.3% | 0.04% | +34.4% |
Buy | TOAST INCcl a | $133,376 | -6.0% | 7,121 | +13.3% | 0.04% | -7.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
UIPATH INC | 9 | Q3 2023 | 30.2% |
DOORDASH INC | 9 | Q3 2023 | 19.6% |
SNOWFLAKE INC | 9 | Q3 2023 | 14.4% |
ACUMEN PHARMACEUTICALS, INC | 9 | Q3 2023 | 10.0% |
908 DEVICES INC | 9 | Q3 2023 | 1.8% |
TARSUS PHARMACEUTICALS INC | 9 | Q3 2023 | 1.4% |
TAYSHA GENE THERAPIES INC | 9 | Q3 2023 | 2.0% |
CANDEL THERAPEUTICS, INC | 9 | Q3 2023 | 1.3% |
SPRUCE BIOSCIENCES INC | 9 | Q3 2023 | 0.7% |
ABSCI CORPORATION | 9 | Q3 2023 | 0.1% |
View Sands Capital Ventures, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G | 2024-02-13 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-15 |
13F-HR | 2023-05-12 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
13F-HR | 2023-02-13 |
13F-HR | 2022-11-09 |
View Sands Capital Ventures, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.